Efficacy and safety of half dose tirofiban assisted PCI for elderly patients with acute ST segment elevation myocardial infarction
Objective:To investigate the efficacy and safety of half-dose tirofiban combined with percutaneous coronary intervention(PCI)in the treatment of elderly patients with acute ST segment elevation myocardial infarction(STEMI).Methods:A total of 98 elderly patients with acute STEMI who were treated in our hospital from January to December 2022 were selected as the research objects,and were randomly divided into control group and study group,with 49 cases in each group.The control group was treated with full-dose tirofiban assisted PCI,and the research group was treated with half-dose tirofiban assisted PCI.The cardiac function,vascular endothelial function,inflammatory reaction,adverse events and bleeding events were compared between the two groups.Results:After one month of treatment,left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),endothelin-1(ET-1),von Willebrand factor(vWF),interleukin(IL-6),tumor necrosis factor-α(TNF-α)and hypersensitive C-reactive protein(hs-CRP)were measured in both groups.Hs-CRP decreased,while left ventricular ejection fraction(LVEF)and nitric oxide(NO)increased significantly,but there was no significant difference between the two groups(P>0.05).The incidence of bleeding in the study group was significantly lower than that in the control group(P<0.05).There was no significant difference in the incidence of other adverse events between the study group and the control group(P>0.05).Conclusion:Half dose tirofiban assisted PCI in elderly patients with acute STEMI will not affect the efficacy,but it can effectively reduce the risk of bleeding,with high safety.
Elderly acute ST segment elevation myocardial infarctionPCI techniqueTirofibanHalf doseSecurity
NETL
NSTL
万方数据
